Solid Biosciences (SLDB) EBIAT: 2017-2024
Historic EBIAT for Solid Biosciences (SLDB) over the last 7 years, with Dec 2024 value amounting to -$42.6 million.
- Solid Biosciences' EBIAT fell 109.48% to -$42.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$124.7 million, marking a year-over-year decrease of 29.88%. This contributed to the annual value of -$124.7 million for FY2024, which is 29.88% down from last year.
- As of Q4 2024, Solid Biosciences' EBIAT stood at -$42.6 million, which was down 30.18% from -$32.7 million recorded in Q3 2024.
- In the past 5 years, Solid Biosciences' EBIAT registered a high of -$15.2 million during Q4 2022, and its lowest value of -$42.6 million during Q4 2024.
- In the last 3 years, Solid Biosciences' EBIAT had a median value of -$24.6 million in 2023 and averaged -$25.6 million.
- As far as peak fluctuations go, Solid Biosciences' EBIAT skyrocketed by 32.95% in 2020, and later plummeted by 109.48% in 2024.
- Quarterly analysis of 4 years shows Solid Biosciences' EBIAT stood at -$21.4 million in 2020, then reached -$15.2 million in 2022, then crashed by 34.22% to -$20.3 million in 2023, then slumped by 109.48% to -$42.6 million in 2024.
- Its last three reported values are -$42.6 million in Q4 2024, -$32.7 million for Q3 2024, and -$25.1 million during Q2 2024.